Univariable analysis | Multivariable analysis* | ||||
---|---|---|---|---|---|
Factors | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value | |
Male | 0.477 (0.136–1.670) | 0.247 | |||
Age (ref. ≥ 70 years) | 0.621 | ||||
19 ~ 29 years | 1.000 (0.045–22.175) | ||||
30 ~ 39 years | 6.000 (0.183-196.271) | ||||
40 ~ 49 years | 2.250 (0.111–45.723) | ||||
50 ~ 59 years | 4.500 (0.190-106.823) | ||||
60 ~ 69 years | 3.500 (0.145–84.694) | ||||
Smoking history | 1.527 (0.350–6.672) | 0.679 | |||
Oral ulcer | 0.778 (0.217–2.793) | 0.700 | |||
Genital ulcer | 0.750 (0.121–4.640) | 0.757 | |||
Ocular lesion | 1.200 (0.212–6.801) | 0.837 | |||
Skin lesion | 2.640 (0.504–13.835) | 0.251 | |||
Arthralgia | 5.000 (0.576–43.388) | 0.144 | 5.000 (0.576–43.388) | 0.144 | |
Previous treatment history | 0.846 (0.081–8.894) | 0.889 | |||
Previous medical history | 1.833 (0.429–7.836) | 0.413 | |||
Concomitant diseases | 2.625 (0.702–9.809) | 0.151 | |||
Concomitant medications | 2.832 (0.358–22.386) | 0.324 | |||
Disease duration (months) | 1.0005 (0.989–1.012) | 0.937 | |||
Total amount of adalimumab (mg) | 1.0001 (0.998–1.002) | 0.916 | |||
Frequency of adalimumab administration (times) | 1.004 (0.939–1.074) | 0.900 |